Once touted as a cure for Covid, hydroxychloroquine (HCQ), the anti-malaria drug, is renewing interest as a potential treatment for the infectious disease and particularly the new fast-spreading Omicron variant.
Two recent studies, not peer-reviewed yet, have debated over whether HCQ is effective against Covid and Omicron. While one claims to be effective against Omicron, the other recommends against its use in Covid patients.
The first study, led by researchers from the University of Glasgow, looks at how antibodies from vaccines block Omicron from entering cells.
The researchers claim that Omicron may have changed the way it enters cells: from cell surface to via endosomes.
Since HCQ is a drug that accumulates in endosomes and makes it less acidic, it cuts the Covid virus’ ability to enter cells. Thus HCQ could act as an antiviral, the researchers claimed.
However, the new study did not test HCQ’s effect on Omicron.
In the second study, a team of researchers Johns Hopkins Bloomberg School of Public Health, and Universities of Utah, Colorado, and Vanderbilt, among others, conducted a meta-analysis of US-based randomised clinical trials (RCTs).
ALSO READ: India’s New Covid Cases Continue to Decline for 2nd Straight Day
The researchers analysed eight RCTs in 770 hospitalized Covid patients and compared HCQ or chloroquine (CQ) and control treatment.
The results did not show evidence of a benefit of HCQ/CQ.
“This study supports the consensus that hydroxychloroquine/chloroquine should not be used to treat hospitalized patients with Covid-19,” the researchers wrote in the study.
HCQ is an anti-malaria medication more commonly used to manage the symptoms of rheumatoid arthritis and autoimmune conditions such as lupus.
In the beginning of the pandemic, the US Food and Drug Administration (FDA) had provided emergency use authorization (EUA) for the use of HCQ and CQ in the treatment of hospitalized Covid patients.
However, most retrospective-observational studies of HCQ/CQ in hospitalized Covid patients provide no evidence supporting the efficacy of this treatment.
(This story has been sourced from a third-party syndicated feed, agencies. Raavi Media accepts no responsibility or liability for the dependability, trustworthiness, reliability, and data of the text. Raavi Media management/ythisnews.com reserves the sole right to alter, delete or remove (without notice) the content at its absolute discretion for any reason whatsoever.)
